{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:45:58Z","timestamp":1791927958418,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertrophic cardiomyopathy (HCM) remains an important cause of sudden cardiac death (SCD), but the biological determinants of ventricular arrhythmic vulnerability remain incompletely defined. This systematic translational review examined whether fibro-inflammatory signaling, fibrotic remodeling, and microvascular ischemia represent convergent components of the arrhythmogenic substrate in HCM. MEDLINE\/PubMed, Embase, Web of Science Core Collection, and Cochrane Library were searched from inception to January 2026. Of 167 records, 37 full-text reports were assessed and 11 studies included. Fibrosis emerged as the most clinically mature substrate marker, while microvascular ischemia appeared to amplify electrical instability, particularly in remodeled myocardium. Molecular and tissue studies suggested upstream fibro-inflammatory programs involving activated fibroblasts, extracellular matrix dysregulation, SMAD\/TGF-beta signaling, CRLF1\/LIFR-JAK-STAT signaling, and altered multicellular communication. Overall, the evidence supports an integrated mechanism-to-substrate model, but prospective outcome-validated studies are needed before these biological layers can refine SCD risk stratification beyond established clinical and imaging markers in contemporary HCM practice.<\/jats:p>","DOI":"10.1007\/s12265-026-10853-w","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:00:28Z","timestamp":1791925228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fibro-Inflammatory Signaling, Fibrosis, and Microvascular Ischemia as Convergent Translational Substrates of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: A Systematic Review"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-5206","authenticated-orcid":false,"given":"Antonio","family":"da Silva Menezes Junior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-4186","authenticated-orcid":false,"given":"Isabela Jube","family":"Wastowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4067-1506","authenticated-orcid":false,"given":"Lilian Carla","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"10853_CR1","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMra2413445","volume":"393","author":"E Braunwald","year":"2025","unstructured":"Braunwald E. Hypertrophic cardiomyopathy. N Engl J Med. 2025;393:1004\u201315. https:\/\/doi.org\/10.1056\/NEJMra2413445.","journal-title":"N Engl J Med"},{"issue":"23","key":"10853_CR2","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Peer Review Committee Members. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239\u2013311. https:\/\/doi.org\/10.1161\/CIR.0000000000001250.","journal-title":"Circulation"},{"key":"10853_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/jcdd12030101","volume":"12","author":"A Kasiakogias","year":"2025","unstructured":"Kasiakogias A, Kaskoutis C, Antoniou CK, Georgopoulos S, Tsiachris D, Arsenos P, Kouroutzoglou A, Klettas D, Vlachopoulos C, Tsioufis K, Gatzoulis K. Exploring the current status of risk stratification in hypertrophic cardiomyopathy: From risk models to promising techniques. J Cardiovasc Dev Dis. 2025;12:101. https:\/\/doi.org\/10.3390\/jcdd12030101.","journal-title":"J Cardiovasc Dev Dis"},{"key":"10853_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2169\/internalmedicine.55.6480","volume":"55","author":"Y Miyaji","year":"2016","unstructured":"Miyaji Y, Iwanaga Y, Nakamura T, Yasuda M, Kawamura T, Miyazaki S. Interrelationship between the myocardial mass, fibrosis, BNP, and clinical outcomes in hypertrophic cardiomyopathy. Intern Med. 2016;55:1261\u20138. https:\/\/doi.org\/10.2169\/internalmedicine.55.6480.","journal-title":"Intern Med"},{"key":"10853_CR5","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/eurheartj\/ehaf464","volume":"46","author":"SK Prasad","year":"2025","unstructured":"Prasad SK, Akbari T, Bishop MJ, Halliday BP, Leyva-Leon F, Marchlinski F. Late gadolinium enhancement imaging and sudden cardiac death. Eur Heart J. 2025;46:3555\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf464.","journal-title":"Eur Heart J"},{"key":"10853_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s44348-025-00054-5","volume":"33","author":"SG Yoon","year":"2025","unstructured":"Yoon SG, Hong GR. Evaluation of sudden cardiac death in hypertrophic cardiomyopathy. J CardioVasc Imaging. 2025;33:14. https:\/\/doi.org\/10.1186\/s44348-025-00054-5.","journal-title":"J CardioVasc Imaging"},{"key":"10853_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/jpm12020294","volume":"12","author":"A Karabinowska-Ma\u0142ocha","year":"2022","unstructured":"Karabinowska-Ma\u0142ocha A, Dziewi\u0119cka E, Bany\u015b P, Urba\u0144czyk-Zawadzka M, Krupi\u0144ski M, Mielnik M, \u0141ach J, Budkiewicz A, Podolec P, \u017bydzik \u0141, Wi\u015bniowska-\u015amia\u0142ek S, Holcman K, Kostkiewicz M, Rubi\u015b P. The relationship between cardiac magnetic resonance-assessed replacement and interstitial fibrosis and ventricular arrhythmias in hypertrophic cardiomyopathy. J Pers Med. 2022;12:294. https:\/\/doi.org\/10.3390\/jpm12020294.","journal-title":"J Pers Med"},{"key":"10853_CR8","doi-asserted-by":"publisher","first-page":"e12656","DOI":"10.1111\/micc.12656","volume":"28","author":"S Aguiar Rosa","year":"2021","unstructured":"Aguiar Rosa S, Rocha Lopes L, Fiarresga A, Ferreira RC, Mota Carmo M. Coronary microvascular dysfunction in hypertrophic cardiomyopathy: Pathophysiology, assessment, and clinical impact. Microcirculation. 2021;28:e12656. https:\/\/doi.org\/10.1111\/micc.12656.","journal-title":"Microcirculation"},{"key":"10853_CR9","doi-asserted-by":"publisher","first-page":"e73325","DOI":"10.7554\/eLife.7332510","volume":"11","author":"RP O\u2019Hara","year":"2022","unstructured":"O\u2019Hara RP, Binka E, Prakosa A, Zimmerman SL, Cartoski MJ, Abraham MR, Lu DY, Boyle PM, Trayanova NA. Personalized computational heart models with T1-mapped fibrotic remodeling predict sudden death risk in patients with hypertrophic cardiomyopathy. eLife. 2022;11:e73325. https:\/\/doi.org\/10.7554\/eLife.7332510.","journal-title":"eLife"},{"key":"10853_CR10","doi-asserted-by":"publisher","first-page":"1641584","DOI":"10.3389\/fcell.2025.1641584","volume":"13","author":"AM Ibrahim","year":"2025","unstructured":"Ibrahim AM, Elfawy HA, Terracciano CM, Yacoub M. Matrisome remodeling in the myocardium of hypertrophic cardiomyopathy; novel targets for molecular diagnostics. Front Cell Dev Biol. 2025;13:1641584. https:\/\/doi.org\/10.3389\/fcell.2025.1641584.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10853_CR11","doi-asserted-by":"publisher","first-page":"41298","DOI":"10.1038\/s41598-025-25140-y","volume":"15","author":"P Marques-Alves","year":"2025","unstructured":"Marques-Alves P, Ferreira MJV, Silva R, Gomes A, Abrunhosa A, Castelo-Branco M, Gon\u00e7alves L. 2-[18F]FDG PET identifies metabolic substrates of sudden cardiac death in hypertrophic cardiomyopathy. Sci Rep. 2025;15(1):41298. https:\/\/doi.org\/10.1038\/s41598-025-25140-y.","journal-title":"Sci Rep"},{"issue":"8","key":"10853_CR12","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/cvr\/cvae086","volume":"120","author":"JA Coleman","year":"2024","unstructured":"Coleman JA, Doste R, Ashkir Z, Coppini R, Sachetto R, Watkins H, Raman B, Bueno-Orovio A. Mechanisms of ischemia-induced arrhythmias in hypertrophic cardiomyopathy: a large-scale computational study. Cardiovascular Res. 2024;120(8):914\u201326. https:\/\/doi.org\/10.1093\/cvr\/cvae086.","journal-title":"Cardiovascular Res"},{"issue":"1","key":"10853_CR13","doi-asserted-by":"publisher","first-page":"bbag036","DOI":"10.1093\/bib\/bbag036","volume":"27","author":"F Huang","year":"2026","unstructured":"Huang F, Zhou M, Chen Y, Hua S, Han Y, Fan Y, Li Q, Sun Z, Yang K, Zhao Q, Jin W. Cross-dataset transcriptomic analyses identify a conserved ENPP2\u2009+\u2009macrophage-fibroblast activation axis in hypertrophic cardiomyopathy. Brief Bioinform. 2026;27(1):bbag036. https:\/\/doi.org\/10.1093\/bib\/bbag036.","journal-title":"Brief Bioinform"},{"key":"10853_CR14","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1038\/s41598-023-30776-9","volume":"13","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang F, Zhang M, Xue H, Fan L, Weng Y. The role of SMAD signaling in hypertrophic obstructive cardiomyopathy: An immunohistopathological study in pediatric and adult patients. Sci Rep. 2023;13:3706. https:\/\/doi.org\/10.1038\/s41598-023-30776-9.","journal-title":"Sci Rep"},{"issue":"11","key":"10853_CR15","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.125.075290","volume":"153","author":"B Lin","year":"2026","unstructured":"Lin B, Wang J, Li C, Wang S, Shen M, Hu L, Chen L, Zhou F, Liu Y, Yang J, Zhang M, Wang D, Xu G, Zhou B, Song L, Shi D, Chen YH. CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy. Circulation. 2026;153(11):845\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.075290.","journal-title":"Circulation"},{"issue":"1","key":"10853_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41421-022-00490-3","volume":"9","author":"X Liu","year":"2023","unstructured":"Liu X, Yin K, Chen L, Chen W, Li W, Zhang T, Sun Y, Yuan M, Wang H, Song Y, Wang S, Hu S, Zhou Z. Lineage-specific regulatory changes in hypertrophic cardiomyopathy unraveled by single-nucleus RNA-seq and spatial transcriptomics. Cell discovery. 2023;9(1):6. https:\/\/doi.org\/10.1038\/s41421-022-00490-3.","journal-title":"Cell discovery"},{"issue":"8","key":"10853_CR17","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.cjca.2025.02.016","volume":"41","author":"S Saboktakin Rizi","year":"2025","unstructured":"Saboktakin Rizi S, Stamenkovic A, Ravandi A. Integrative Omics Approaches in Cardiovascular Disease Research: Current Trends and Future Directions. Can J Cardiol. 2025;41(8):1642\u20135. https:\/\/doi.org\/10.1016\/j.cjca.2025.02.016.","journal-title":"Can J Cardiol"},{"issue":"3","key":"10853_CR18","doi-asserted-by":"publisher","first-page":"pbaf016","DOI":"10.1093\/pcmedi\/pbaf016","volume":"8","author":"XY Yang","year":"2025","unstructured":"Yang XY, Li YM, Wang JY, Jia YH, Yi Z, Chen M. Utilizing multimodal artificial intelligence to advance cardiovascular diseases. Precision Clin Med. 2025;8(3):pbaf016. https:\/\/doi.org\/10.1093\/pcmedi\/pbaf016.","journal-title":"Precision Clin Med"},{"key":"10853_CR19","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Moher D. The PRISMA 2020 statement:An updated guideline for reporting systematic reviews. Int J Surg (London England). 2021;88:105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906.","journal-title":"Int J Surg (London England)"},{"key":"10853_CR20","doi-asserted-by":"crossref","unstructured":"Aromataris E, Munn Z, editors. JBI manual for evidence synthesis. Joanna Briggs Institute; 2024.","DOI":"10.46658\/JBIMES-24-01"},{"key":"10853_CR21","doi-asserted-by":"publisher","unstructured":"\u00dclgen Kunak A, Kunak T. Association between uric acid-to-albumin ratio and clinical outcomes in patients with hypertrophic cardiomyopathy: a retrospective observational study. J Int Med Res. 2026;54. https:\/\/doi.org\/10.1177\/0300060525141262322.","DOI":"10.1177\/0300060525141262322"},{"key":"10853_CR22","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/J.THROMRES.2010.01.010","volume":"126","author":"F Cambronero","year":"2010","unstructured":"Cambronero F, Vilchez JA, Garc\u00eda-Honrubia A, Ruiz-Espejo F, Moreno V, Hern\u00e1ndez-Romero D, Bonacasa B, Gonz\u00e1lez-Conejero R, de la Morena G, Mart\u00ednez P, Climent V, Vald\u00e9s M, Mar\u00edn F. Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy. Thromb Res. 2010;126:e46\u201350. https:\/\/doi.org\/10.1016\/J.THROMRES.2010.01.010.","journal-title":"Thromb Res"},{"issue":"10","key":"10853_CR23","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/clc.23425","volume":"43","author":"L Liu","year":"2020","unstructured":"Liu L, Liu S, Shen L, Tu B, Hu Z, Hu F, Zheng L, Ding L, Fan X, Yao Y. Correlations between cardiac troponin I and nonsustained ventricular tachycardia in hypertrophic obstructive cardiomyopathy. Clin Cardiol. 2020;43(10):1150\u20139. https:\/\/doi.org\/10.1002\/clc.23425.","journal-title":"Clin Cardiol"},{"issue":"11","key":"10853_CR24","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa025050","volume":"349","author":"F Cecchi","year":"2003","unstructured":"Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349(11):1027\u201335. https:\/\/doi.org\/10.1056\/NEJMoa025050.","journal-title":"N Engl J Med"},{"issue":"1","key":"10853_CR25","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1038\/s41598-020-80868-z","volume":"11","author":"K Sonnenschein","year":"2021","unstructured":"Sonnenschein K, Fiedler J, de Gonzalo-Calvo D, Xiao K, Pfanne A, Just A, Zwadlo C, Soltani S, Bavendiek U, Kraft T, Remedios D, Cebotari C, Bauersachs S, J., Thum T. Blood-based protein profiling identifies serum protein c-KIT as a novel biomarker for hypertrophic cardiomyopathy. Sci Rep. 2021;11(1):1755. https:\/\/doi.org\/10.1038\/s41598-020-80868-z.","journal-title":"Sci Rep"},{"key":"10853_CR26","doi-asserted-by":"publisher","unstructured":"Ismail, T. F., Jabbour, A., Gulati, A., Mallorie, A., Raza, S., Cowling, T. E., Das,B., Khwaja, J., Alpendurada, F. D., Wage, R., Roughton, M., McKenna, W. J., Moon,J. C., Varnava, A., Shakespeare, C., Cowie, M. R., Cook, S. A., Elliott, P., O\u2019Hanlon,R., Pennell, D. J., \u2026 Prasad, S. K. (2014). Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart (British Cardiac Society), 100(23), 1851\u20131858. https:\/\/doi.org\/10.1136\/heartjnl-2013-305471.","DOI":"10.1136\/heartjnl-2013-305471."},{"issue":"2","key":"10853_CR27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s12350-022-03040-2","volume":"30","author":"AA Giannopoulos","year":"2023","unstructured":"Giannopoulos AA, Buechel RR, Kaufmann PA. Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies. J nuclear cardiology: official publication Am Soc Nuclear Cardiol. 2023;30(2):800\u201310. https:\/\/doi.org\/10.1007\/s12350-022-03040-2.","journal-title":"J nuclear cardiology: official publication Am Soc Nuclear Cardiol"},{"key":"10853_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jjcc.2015.07.020","volume":"68","author":"M Klopotowski","year":"2016","unstructured":"Klopotowski M, Kukula K, Malek LA, Spiewak M, Polanska-Skrzypczyk M, Jamiolkowski J, Dabrowski M, Baranowski R, Klisiewicz A, Kusmierczyk M, Jasinska A, Jarmus E, Kruk M, Ruzyllo W, Witkowski A, Chojnowska L. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. J Cardiol. 2016;68:49\u201356. https:\/\/doi.org\/10.1016\/j.jjcc.2015.07.020.","journal-title":"J Cardiol"},{"key":"10853_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jcmg.2023.07.005","volume":"17","author":"A Kiaos","year":"2024","unstructured":"Kiaos A, Daskalopoulos GN, Kamperidis V, Ziakas A, Efthimiadis G, Karamitsos TD. Quantitative late gadolinium enhancement cardiac magnetic resonance and sudden death in hypertrophic cardiomyopathy: A meta-analysis. JACC Cardiovasc Imaging. 2024;17:489\u201397. https:\/\/doi.org\/10.1016\/j.jcmg.2023.07.005.","journal-title":"JACC Cardiovasc Imaging"},{"key":"10853_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12968-020-00610-6","volume":"22","author":"J Schulz-Menger","year":"2020","unstructured":"Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, Kim RJ, von Knobelsdorff-Brenkenhoff F, Kramer CM, Pennell DJ, Plein S, Nagel E. Standardized image interpretation and post-processing in cardiovascular magnetic resonance\u20142020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing. J Cardiovasc Magn Reson. 2020;22:19. https:\/\/doi.org\/10.1186\/s12968-020-00610-6.","journal-title":"J Cardiovasc Magn Reson"},{"key":"10853_CR31","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.3390\/jcm14051781","volume":"14","author":"C Mann","year":"2025","unstructured":"Mann C, Dachs TM, Gharib D, Widmann K, Tosun R, Srdits M, Kronberger C, Beitzke D, Loewe C, Kammerlander AA, Gwechenberger M, Lang IM, Hengstenberg C, Zelniker TA, Dalos D. The prognostic implication of late gadolinium enhancement quantification and syncope in hypertrophic cardiomyopathy. J Clin Med. 2025;14:1781. https:\/\/doi.org\/10.3390\/jcm14051781.","journal-title":"J Clin Med"},{"key":"10853_CR32","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, Cecchi F, Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivotto I. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138:1387\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.033200.","journal-title":"Circulation"},{"issue":"15","key":"10853_CR33","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.125.076036","volume":"153","author":"CR Vissing","year":"2026","unstructured":"Vissing CR, Axelsson Raja A, Helms AS, Saberi S, Owens AT, Rossano JW, Abrams DJ, Ingles J, Gray B, Lampert R, Stendahl JC, Lakdawala NK, Ware JS, Parikh VN, Michels M, Crotti L, Ryan TD, Olivotto I, Day SM, Bundgaard H, Ho CY. Differences in Disease Trajectory,Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. Circulation. 2026;153(15):1104\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.076036.","journal-title":"Circulation"},{"key":"10853_CR34","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1161\/CIRCULATIONAHA.111.045658","volume":"124","author":"SR Dukkipati","year":"2011","unstructured":"Dukkipati SR, d\u2019Avila A, Soejima K, et al. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. Circulation. 2011;124:1850\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.045658.","journal-title":"Circulation"},{"issue":"8","key":"10853_CR35","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.hrthm.2010.05.022","volume":"7","author":"P Santangeli","year":"2010","unstructured":"Santangeli P, Di Biase L, Lakkireddy D, Burkhardt JD, Pillarisetti J, Michowitz Y, Sanchez JE, Horton R, Mohanty P, Gallinghouse GJ, Russo D, Casella A, Pelargonio M, Santarelli G, Verma P, Narasimhan A, Shivkumar C, K., Natale A. Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy: safety and feasibility. Heart rhythm. 2010;7(8):1036\u201342. https:\/\/doi.org\/10.1016\/j.hrthm.2010.05.022.","journal-title":"Heart rhythm"},{"key":"10853_CR36","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","volume":"69","author":"EJ Rowin","year":"2017","unstructured":"Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, Maron MS. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol. 2017;69:761\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.063.","journal-title":"J Am Coll Cardiol"},{"key":"10853_CR37","doi-asserted-by":"publisher","first-page":"e73325","DOI":"10.7554\/eLife.73325","volume":"11","author":"RP O\u2019Hara","year":"2022","unstructured":"O\u2019Hara RP, Binka E, Prakosa A, Zimmerman SL, Cartoski MJ, Abraham MR, Lu DY, Boyle PM, Trayanova NA. Personalized computational heart models with T1-mapped fibrotic remodeling predict sudden death risk in patients with hypertrophic cardiomyopathy. eLife. 2022;11:e73325. https:\/\/doi.org\/10.7554\/eLife.73325.","journal-title":"eLife"},{"key":"10853_CR38","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3390\/biomedicines13061327","volume":"13","author":"I Ogurek","year":"2025","unstructured":"Ogurek I, Mendpara A, Hirani K, Aman M, Kendale S, Rawani S, Jaber W, Gajjar M, Beer D, Bauer A, Krishnaswamy A, Desai MY. A narrative review of current and investigational therapies for hypertrophic cardiomyopathy. Biomedicines. 2025;13:1327. https:\/\/doi.org\/10.3390\/biomedicines13061327.","journal-title":"Biomedicines"},{"key":"10853_CR39","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X.","journal-title":"Lancet"},{"issue":"10293","key":"10853_CR40","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","volume":"397","author":"JA Spertus","year":"2021","unstructured":"Spertus JA, Fine JT, Elliott P, Ho CY, Olivotto I, Saberi S, Li W, Dolan C, Reaney M, Sehnert AJ, Jacoby D. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England). 2021;397(10293):2467\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(21)00763-7.","journal-title":"Lancet (London England)"},{"key":"10853_CR41","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","volume":"131","author":"MS Maron","year":"2018","unstructured":"Maron MS, Chan RH, Kapur NK, Jaffe IZ, McGraw AP, Kerur R, Maron BJ, Udelson JE. Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy. Am J Med. 2018;131:837\u201341. https:\/\/doi.org\/10.1016\/j.amjmed.2018.02.025.","journal-title":"Am J Med"},{"key":"10853_CR42","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","volume":"122","author":"K Abozguia","year":"2010","unstructured":"Abozguia K, Elliott P, McKenna W, Phan TT, Nallur Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.934059.","journal-title":"Circulation"},{"key":"10853_CR43","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","volume":"4","author":"CJ Coats","year":"2019","unstructured":"Coats CJ, Pavlou M, Watkinson OT, et al. Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiol. 2019;4:230\u20135. https:\/\/doi.org\/10.1001\/jamacardio.2018.4847.","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10853_CR44","doi-asserted-by":"publisher","first-page":"e028293","DOI":"10.1161\/JAHA.122.028293","volume":"12","author":"M Huang","year":"2023","unstructured":"Huang M, Zhang J, Song C, Wang S, Zhou Z, Wang H, Zhao S, Yin K, Li L, Yang S, Zheng X, Lu J, Huang X. SARC Gene Mutation Is Associated With Myocardial Fibrosis Measured by Histopathology and Cardiac Magnetic Resonance in Patients With Hypertrophic Cardiomyopathy. J Am Heart Association. 2023;12(5):e028293. https:\/\/doi.org\/10.1161\/JAHA.122.028293.","journal-title":"J Am Heart Association"},{"key":"10853_CR45","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jchf.2014.08.003","volume":"3","author":"CY Ho","year":"2015","unstructured":"Ho CY, Lakdawala NK, Cirino AL, Lipshultz SE, Sparks E, Abbasi SA, Kwong RY, Antman EM, Semsarian C, Gonz\u00e1lez A, L\u00f3pez B, D\u00edez J, Orav EJ, Colan SD, Seidman JG, Seidman CE. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Heart Fail. 2015;3:180\u20138. https:\/\/doi.org\/10.1016\/j.jchf.2014.08.003.","journal-title":"JACC Heart Fail"},{"key":"10853_CR46","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/eurheartj\/ehn111","volume":"29","author":"RC Saumarez","year":"2008","unstructured":"Saumarez RC, Pytkowski M, Sterlinski M, Bourke JP, Clague JR, Cobbe SM, Connelly DT, Griffith MJ, McKeown PP, McLeod K, Morgan JM, Sadoul N, Chojnowska L, Huang CLH, Grace AA. Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J. 2008;29:1653\u201361. https:\/\/doi.org\/10.1093\/eurheartj\/ehn111.","journal-title":"Eur Heart J"},{"key":"10853_CR47","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1161\/01.CIR.0000068347.32847.8E","volume":"107","author":"RC Saumarez","year":"2003","unstructured":"Saumarez RC, Chojnowska L, Derksen R, et al. Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation. Circulation. 2003;107:2595\u2013600. https:\/\/doi.org\/10.1161\/01.CIR.0000068347.32847.8E.","journal-title":"Circulation"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10853-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-026-10853-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10853-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:00:30Z","timestamp":1791925230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-026-10853-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10853"],"URL":"https:\/\/doi.org\/10.1007\/s12265-026-10853-w","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests relevant to this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"133"}}